Completed PHASE1 INTERVENTIONAL 1-arm NCT00187174

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors

Sponsor: Novartis

Conditions Brain Tumors Rhabdomyosarcoma Sarcoma, Soft Tissue Tumors

Interventions Everolimus

Updated 6 times since 2017 Last updated: Mar 3, 2015 Started: Oct 31, 2004 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Brain Tumors and Rhabdomyosarcoma, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
St. Jude Children's Research Hospital

Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Memphis, United States